As p53 is one of the most frequently mutated tumour suppressors in human cancer [15], and meanwhile, the stability of mutated p53 (R249S) protein is equally regulated by USP33, therefore, specific targeting USP33 in a subset of human cancer with p53 mutation (R249S) might yield potential translational value in clinal cancer treatment. The gene discussed is TP53; the disease is neoplasm.